A blood-based colorectal cancer screening test called Shield, developed by Guardant Health, has shown promise in detecting cancer in individuals who may not undergo traditional colonoscopies. The test analyzes DNA fragments shed by tumors into the bloodstream, demonstrating 83% sensitivity and 90% specificity in clinical trials. While not a replacement for colonoscopies, Shield offers a lower-friction alternative for the millions who avoid or delay the gold standard screening due to factors like fear, access, or cost. Recent guidelines now include blood-based testing as a viable screening option. AI
IMPACT Offers a less invasive screening option for millions, potentially improving early detection rates for colorectal cancer.
RANK_REASON The article discusses a new product (Shield blood test) that offers an alternative screening method for a disease, but it is not a frontier model release or a significant industry-wide shift.
- American Cancer Society
- colonoscopy
- colorectal cancer
- Dr. Craig Eagle
- Guardant Health
- Kim Turner
- Medicare
- Shield
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
